- Home
- APRE vs BCDA Comparison
APRE vs BCDA Comparison
Compare APRE & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- BCDA
- Stock Information
- Founded
- APRE 2006
- BCDA N/A
- Country
- APRE United States
- BCDA United States
- Employees
- APRE N/A
- BCDA N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- BCDA Health Care
- Exchange
- APRE Nasdaq
- BCDA Nasdaq
- Market Cap
- APRE 9.7M
- BCDA 10.1M
- IPO Year
- APRE 2019
- BCDA N/A
- Fundamental
- Price
- APRE $1.75
- BCDA $2.17
- Analyst Decision
- APRE Strong Buy
- BCDA Strong Buy
- Analyst Count
- APRE 2
- BCDA 1
- Target Price
- APRE $15.50
- BCDA $25.00
- AVG Volume (30 Days)
- APRE 35.7K
- BCDA 63.3K
- Earning Date
- APRE 05-14-2025
- BCDA 05-14-2025
- Dividend Yield
- APRE N/A
- BCDA N/A
- EPS Growth
- APRE N/A
- BCDA N/A
- EPS
- APRE N/A
- BCDA N/A
- Revenue
- APRE $1,284,475.00
- BCDA $3,000.00
- Revenue This Year
- APRE N/A
- BCDA N/A
- Revenue Next Year
- APRE N/A
- BCDA N/A
- P/E Ratio
- APRE N/A
- BCDA N/A
- Revenue Growth
- APRE 33.27
- BCDA N/A
- 52 Week Low
- APRE $1.41
- BCDA $1.63
- 52 Week High
- APRE $5.01
- BCDA $5.04
- Technical
- Relative Strength Index (RSI)
- APRE 49.51
- BCDA 47.00
- Support Level
- APRE $1.60
- BCDA $1.80
- Resistance Level
- APRE $2.00
- BCDA $2.31
- Average True Range (ATR)
- APRE 0.16
- BCDA 0.18
- MACD
- APRE 0.02
- BCDA -0.00
- Stochastic Oscillator
- APRE 37.50
- BCDA 53.70
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).